课题基金 / 基金详情

CLINICAL TRIAL: PX-171-001-PHASE I STUDY OF ESCALATING DOSES OF PROTEASOME INHIB

CLINICAL TRIAL: PX-171-001-PHASE I STUDY OF ESCALATING DOSES OF PROTEASOME INHIB
临床试验:PX-171-001-蛋白酶体抑制剂剂量递增的 I 期研究
批准号:
7716842
负责人:
PETER VOORHEES
金额:
$0.42万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-02 至 2008-05-31

项目摘要

项目成果

PETER VOORHEES的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金, 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是了解一种名为PR-171的研究药物在不同剂量水平下的安全性。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to learn about the safety of an investigational drug called PR-171 at different dose levels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
LCCC 0406: ADDITION OF CELLCEPT TO GLEEVEC IN THE TREATMENT OF LEUKEMIA
LCCC 0406: ADDITION OF CELLCEPT TO GLEEVEC IN THE TREATMENT OF LEUKEMIA
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)